Asthma is a complex disease of the airways that develops as a
consequence of both genetic and environmental factors. This interaction
has highlighted genes important in early life, particularly those that
control lung development, such as the Wingless/Integrase-1 (WNT)
signalling pathway. Although aberrant WNT signalling is involved with
an array of human conditions, it has received little attention within the
context of asthma. Yet it is highly relevant, driving events involved with
inflammation, airway remodelling, and airway hyper-responsiveness
(AHR). In this review, we revisit asthma therapeutics by examining
whether WNT signalling is a valid therapeutic target for asthma.